论文部分内容阅读
目的：观察噻氯匹定对急性脑梗死的疗效及对血小板α颗粒膜蛋白（ＣＤ６２Ｐ） 及血小板溶酶体完整膜蛋白（ＣＤ６３） 的影响。方法：２ 组（ 各３０ 例） 均给予一般性治疗（ 甘露醇、川芎嗪、卡托普利及格列齐特） ，噻氯匹定组另予噻氯匹定２５０ ｍｇ ， ｐｏ，ｑｄ ×３０ｄ 。治疗前后做ＣＤ６２Ｐ， ＣＤ６３ 含量检测及疗效评定。结果：急性脑梗死病人ＣＤ６２Ｐ及ＣＤ６３ 含量比正常对照明显增高（ Ｐ＜ ０ ．０１） ， 治疗３０ ｄ 后明显降低（ Ｐ＜０ ．０１） ；噻氯匹定组总有效率（８０ ％ ） 高于对照组（５３ ％ ） 。结论：噻氯匹定能抑制急性脑梗死病人血小板的激活，减少对脑的损害，促进神经功能恢复，可用于治疗急性脑梗死。
Objective: To observe the effect of ticlopidine on acute cerebral infarction and its effect on platelet α-granule membrane protein (CD62P) and platelet lysosome intact membrane protein (CD63). Methods: The general treatment (mannitol, ligustrazine, captopril and gliclazide) was given in two groups (30 cases each). The ticlopidine group was given ticlopidine 250 mg, po, qd for 30 days . Before and after treatment to do CD62P, CD63 content and efficacy evaluation. Results: The levels of CD62P and CD63 in patients with acute cerebral infarction were significantly higher than those in normal controls (P <0.01), and decreased significantly after 30 days of treatment (P <0.01). The total effective rate (80%) was higher in ticlopidine group In the control group (53%). Conclusion: Ticlopidine can inhibit the activation of platelet in patients with acute cerebral infarction, reduce the damage to the brain and promote the recovery of nerve function, which can be used to treat acute cerebral infarction.